Antengene 경영진

경영진 기준 점검 2/4

Antengene CEO는 Jay Mei, Aug2020 에 임명되었습니다 의 임기는 5.83 년입니다. 총 연간 보상은 CN¥13.90M, 46.7% 급여 및 53.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 €65.91M 가치에 해당하는 회사 주식의 25.93% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.8 년과 5 년입니다.

핵심 정보

Jay Mei

최고경영자

CN¥13.9m

총 보수

CEO 급여 비율	46.67%
CEO 재임 기간	5.8yrs
CEO 지분 보유율	25.9%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	5yrs

최근 경영진 업데이트

Recent updates

CEO 보수 분석

Jay Mei의 보수는 Antengene의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Dec 31 2025	CN¥14m	CN¥6m	-CN¥239m
Sep 30 2025	n/a	n/a	-CN¥234m
Jun 30 2025	n/a	n/a	-CN¥229m
Mar 31 2025	n/a	n/a	-CN¥274m
Dec 31 2024	CN¥13m	CN¥6m	-CN¥319m
Sep 30 2024	n/a	n/a	-CN¥424m
Jun 30 2024	n/a	n/a	-CN¥530m
Mar 31 2024	n/a	n/a	-CN¥555m
Dec 31 2023	CN¥17m	CN¥6m	-CN¥581m
Sep 30 2023	n/a	n/a	-CN¥628m
Jun 30 2023	n/a	n/a	-CN¥676m
Mar 31 2023	n/a	n/a	-CN¥639m
Dec 31 2022	CN¥15m	CN¥6m	-CN¥601m
Sep 30 2022	n/a	n/a	-CN¥584m
Jun 30 2022	n/a	n/a	-CN¥567m
Mar 31 2022	n/a	n/a	-CN¥611m
Dec 31 2021	CN¥17m	CN¥5m	-CN¥656m

보상 대 시장: Jay의 총 보수(USD2.06M)는 German 시장에서 비슷한 규모 기업의 평균(USD765.44K)보다 높습니다.

보상과 수익: Jay의 보상은 회사가 적자임에도 증가했습니다.

CEO

Jay Mei (61 yo)

5.8yrs

재임 기간

CN¥13,900,000

보수

Dr. Jay Mei, M.D. & Ph.D. is the Founder of Antengene Corporation and serves as Chairman and Chief Executive Officer since August 18, 2020. He has been Director of Antengene Corporation since August 28, 20...

리더십 팀

이름	직위	재임 기간	보수	지분
Jay Mei	Founder	5.8yrs	CN¥13.90m	25.93% € 65.9m
Donald Andrew Lung	CFO & Executive Director	6yrs	CN¥3.76m	0.074% € 188.0k
Yiteng Liu	Chief Operating Officer	5.8yrs	데이터 없음	데이터 없음
Thomas Karalis	Corporate VP & Head of Asia Pacific Region	6.2yrs	데이터 없음	데이터 없음
Yang Cao	Joint Company Secretary	no data	데이터 없음	데이터 없음
Rui Guo	Executive Officer	no data	데이터 없음	데이터 없음
Hou Bing	Chief Scientific Officer	less than a year	데이터 없음	데이터 없음
Shimin Sun	Corporate VP and Head of Clinical Enabling Functions & Operational Excellence	no data	데이터 없음	데이터 없음
Dirk Hoenemann	VP and Head of Medical Affairs for APAC & Early Clinical Development	5.9yrs	데이터 없음	데이터 없음
Wai Chiu Wong	Joint Company Secretary	4.3yrs	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

52.5yo

평균 나이

경험이 풍부한 관리: 722의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.8 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Jay Mei	Founder	7.8yrs	CN¥13.90m	25.93% € 65.9m
Donald Andrew Lung	CFO & Executive Director	5yrs	CN¥3.76m	0.074% € 188.0k
Ricky Johnstone	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Shaji K. Kumar	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yi-Long Wu	Member of Scientific Advisory Board	3.4yrs	데이터 없음	데이터 없음
Robert Gale	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jing Qian	Independent Non-Executive Director	5.6yrs	CN¥295.00k	데이터 없음
Sheng Tang	Independent Non-Executive Director	5.6yrs	CN¥295.00k	데이터 없음
Rafael Fonseca	Independent Non-Executive Director	3.2yrs	CN¥269.00k	데이터 없음
Wei-Li Zhao	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jayesh Desai	Member of Scientific Advisory Board	3.4yrs	데이터 없음	데이터 없음

5.0yrs

평균 재임 기간

50yo

평균 나이

경험이 풍부한 이사회: 722의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/06/17 08:53
종가	2026/06/17 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Antengene Corporation Limited는 6명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Ziyu He	China International Capital Corporation Limited
Wangbin Zhou	Citigroup Inc
null null	CMB International Securities Limited

Antengene 경영진

경영진 기준 점검 2/4

핵심 정보

최근 경영진 업데이트

Antengene Corporation Limited Appoints Bing Hou as Chief Scientific Officer

Insufficient new directors

Antengene Corporation Limited, Annual General Meeting, Jun 10, 2026

Antengene Corporation Limited, Annual General Meeting, Jun 13, 2025

Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Recent updates

Antengene Presents First Preclinical Data on ATG-207 At EULAR 2026

Antengene Corporation Limited Presents First Preclinical Data On ATG-207 (aCD3-TGF-ß Bifunctional Fusion Protein) At EULAR 2026

Antengene Corporation Limited Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer

Antengene Corporation Limited Appoints Bing Hou as Chief Scientific Officer

Insufficient new directors

Antengene Corporation Limited Presents Three Novel Programs At AACR 2026

Antengene Corporation Limited, Annual General Meeting, Jun 10, 2026

Antengene Corporation Limited Presents Preclinical Results For Next-Generation ADCs And AnTenGager™ TCEs

Antengene Corporation Limited to Report Fiscal Year 2025 Results on Mar 20, 2026

Antengene Corporation Limited Announces That South Korea'snational Health Insurance Service (Nhis) Has Approved the Reimbursement of Xpovio

Antengene Corporation Limited Presents Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

Antengene Corporation Limited Expands XPOVIO Indications in Malaysia with Approval in Diffuse Large B-Cell Lymphoma

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with Keytruda (Pembrolizumab) +- Chemotherapy

Antengene Corporation Limited Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs

Antengene Corporation Limited Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expansion Levels and Exceptional Tolerability

Antengene Corporation Limited Announces 2025 Interim Results with Encouraging Clinical Data and Progress in TCE Platform

Antengene Corporation Limited's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

Antengene Corporation Limited to Report First Half, 2025 Results on Aug 22, 2025

Antengene Corporation Limited to Present Latest Clinical Results from Two Studies in CPI-Resistant Solid Tumors at ASCO 2025

Antengene Corporation Limited Releases Results from Four Preclinical Studies in Poster Presentations At the 2025 American Association for Cancer Research Annual Meeting

Antengene Corporation Limited, Annual General Meeting, Jun 13, 2025

Antengene Corporation Limited to Report Fiscal Year 2024 Results on Mar 21, 2025

Antengene Corporation Limited Announces Approval of NDA by the Indonesia National Agency of Drug and Food Control for XPOVIO

Antengene Corporation Limited Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025

Antengene Corporation Limited Announces Xpovio's New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to Dlbcl Patients in the Country

South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO

First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023)

Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications

First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023)

Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024

Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024

Antengene Corporation Limited Announces China National Medical Products Administration Approves New Indication in DLBCL in China, Bringing A New Treatment Option to Patients in the Country

Full year 2023 earnings released: CN¥0.94 loss per share (vs CN¥0.97 loss in FY 2022)

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

New minor risk - Market cap size

Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance

Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022)

Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023

Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Less than half of directors are independent

Antengene Corporation Limited Announces Executive Changes

Less than half of directors are independent

Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer

Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting

Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037

Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma

First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021)

Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022

Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress